RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis

Rhea-AI Summary

RAPT Therapeutics (Nasdaq: RAPT) announced it will release top-line results from its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis on June 14, 2021. This key data announcement signifies the company's ongoing commitment to addressing unmet medical needs in inflammatory diseases. The results will be shared during a conference call at 8:30 a.m. ET, which will be accessible via a live webcast. RAPT is developing targeted oral therapies focusing on CCR4, with RPT193 as a notable candidate in its pipeline.

Positive

• Upcoming release of top-line data from Phase 1b trial of RPT193 for atopic dermatitis.
• RAPT is advancing drug candidates targeting CCR4, enhancing its potential in oncology and inflammatory diseases.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company plans to report top line data from its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis (AD) in a premarket press release and webcast on Monday, June 14, 2021.

RAPT will host a conference call accompanied by a slide presentation at 8:30 a.m. ET on Monday, June 14th. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The call can be accessed by dialing (833) 672-0665 (domestic) or (929) 517-0344 (international) and referring to conference ID 4696044. The webcast will be available for replay for 30 days. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

FAQ

What is the purpose of RAPT Therapeutics' Phase 1b clinical trial of RPT193?

The Phase 1b clinical trial of RPT193 is aimed at evaluating its efficacy and safety in treating moderate to severe atopic dermatitis.

When will RAPT announce the results of its clinical trial?

RAPT Therapeutics plans to announce the top-line results on June 14, 2021.

How can investors access the results from RAPT Therapeutics' trial?

Investors can access the results during a conference call on June 14, 2021, at 8:30 a.m. ET, via a live webcast on RAPT's website.

What is RPT193 targeting in the clinical trial?

RPT193 is targeting the treatment of moderate to severe atopic dermatitis in patients.

What is the significance of the CCR4 target for RAPT Therapeutics?

CCR4 is a critical immune driver that RAPT's drug candidates aim to modulate, which could provide new therapies for cancer and inflammatory diseases.